Celgene Agrees to $7.2 Billion Deal for Receptos

July 14, 2015 9:53 PM

41 0

The biotechnology company Celgene agreed Tuesday to pay $7.2 billion in cash to acquire Receptos, which is developing a potentially promising drug for autoimmune diseases.

Celgene will pay $232 a share, a 12 percent premium to Receptos’s closing price on Tuesday. The deal was announced after markets had closed.

Also read: Exxon Mobil Expands Permian Basin Footprint in Deal Worth More Than $5.6 Billion

Read more

To category page

Loading...